Literature DB >> 32842804

Immune checkpoint inhibitors and corneal transplant rejection: a call for awareness.

Harpal Singh Sandhu1, Houman D Hemmati2, Reza Dana3.   

Abstract

Entities:  

Keywords:  autoimmunity; cancer immunology; cellular immunology; checkpoint inhibitors; clinical immunology; immunity-adaptive; immunoprivilege; immunotherapy; molecular immunology; transplantation

Year:  2020        PMID： 32842804      PMCID： PMC7482051          DOI： 10.2217/imt-2020-0100

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


× No keyword cloud information.
  14 in total

1.  New thoughts on the immunology of corneal transplantation.

Authors:  J W Streilein
Journal:  Eye (Lond)       Date:  2003-11       Impact factor: 3.775

2.  B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts.

Authors:  Junko Hori; Mingcong Wang; Megumi Miyashita; Keiko Tanemoto; Hiroshi Takahashi; Toshitada Takemori; Ko Okumura; Hideo Yagita; Miyuki Azuma
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

3.  Differential effects of costimulatory pathway modulation on corneal allograft survival.

Authors:  Martin P Watson; Andrew J T George; Daniel F P Larkin
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-08       Impact factor: 4.799

4.  Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses.

Authors:  Astrid Starke; Maja T Lindenmeyer; Stephan Segerer; Matthias A Neusser; Barbara Rüsi; Daniel M Schmid; Clemens D Cohen; Rudolf P Wüthrich; Thomas Fehr; Ying Waeckerle-Men
Journal:  Kidney Int       Date:  2010-04-14       Impact factor: 10.612

Review 5.  Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?

Authors:  Pauline De Bruyn; Dirk Van Gestel; Piet Ost; Vibeke Kruse; Lieve Brochez; Hans Van Vlierberghe; Arnaud Devresse; Véronique Del Marmol; Alain Le Moine; Sandrine Aspeslagh
Journal:  Curr Opin Oncol       Date:  2019-03       Impact factor: 3.645

6.  Suppression of bystander T helper 1 cells by iris pigment epithelium-inducing regulatory T cells via negative costimulatory signals.

Authors:  Sunao Sugita; Shintaro Horie; Yukiko Yamada; Hiroshi Keino; Yoshihiko Usui; Masaru Takeuchi; Manabu Mochizuki
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-03       Impact factor: 4.799

7.  The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.

Authors:  Vivek Kumar; Atul B Shinagare; Helmut G Rennke; Sandeep Ghai; Jochen H Lorch; Patrick A Ott; Osama E Rahma
Journal:  Oncologist       Date:  2020-02-11

8.  Human corneal endothelial cells expressing programmed death-ligand 1 (PD-L1) suppress PD-1+ T helper 1 cells by a contact-dependent mechanism.

Authors:  Sunao Sugita; Yoshihiko Usui; Shintaro Horie; Yuri Futagami; Yukiko Yamada; Juan Ma; Takeshi Kezuka; Hirofumi Hamada; Tomohiko Usui; Manabu Mochizuki; Satoru Yamagami
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-09-04       Impact factor: 4.799

9.  Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.

Authors:  Noha Abdel-Wahab; Houssein Safa; Ala Abudayyeh; Daniel H Johnson; Van Anh Trinh; Chrystia M Zobniw; Heather Lin; Michael K Wong; Maen Abdelrahim; A Osama Gaber; Maria E Suarez-Almazor; Adi Diab
Journal:  J Immunother Cancer       Date:  2019-04-16       Impact factor: 13.751

10.  Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients.

Authors:  Sandhya Manohar; Charat Thongprayoon; Wisit Cheungpasitporn; Svetomir N Markovic; Sandra M Herrmann
Journal:  Kidney Int Rep       Date:  2019-12-07
View more
  1 in total

Review 1.  Corneal Transplant Rejections in Patients Receiving Immune Checkpoint Inhibitors.

Authors:  Majid Moshirfar; Noor F Basharat; Tanner S Seitz; Briana K Ply; Yasmyne C Ronquillo; Phillip C Hoopes
Journal:  J Clin Med       Date:  2022-09-25       Impact factor: 4.964
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.